Antiviral mechanism and biochemical basis of the human APOBEC3 family

Frontiers in Microbiology

Volumn 3, Issue JUL, 2012, Pages

  Imahashi, Mayumi ^a,b   Nakashima, Masaaki ^a,c   Iwatani, Yasumasa ^a,b  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

Antiviral; APOBEC3; APOBEC3G; Cytidine deaminase; HIV; Retrovirus; Reverse transcription; Vif

Indexed keywords

EID: 84874342254     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2012.00250     Document Type: Article

References (88)

1. ′ untranslated region of c-myc increases mRNA stability. Mol. Cell. Biol. 20, 1982-1992.
2. Anant, S., MacGinnitie, A. J., and Davidson, N. O. (1995). apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNAbinding protein. J. Biol. Chem. 270, 14762-14767.
3. Anderson, J. L., and Hope, T. J. (2008). APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology 375, 1-12.
4. Beale, R. C., Petersen-Mahrt, S. K.,Watt, I. N.,Harris,R. S.,Rada,C.,and Neuberger, M. S. (2004). Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337, 585-596.
5. Bennett, R. P., Salter, J. D., Liu, X., Wedekind, J. E., and Smith, H. C. (2008). APOBEC3G subunits self-associate via the C-terminal deaminase domain. J. Biol. Chem. 283, 33329-33336.
6. Bishop, K. N., Verma, M., Kim, E. Y., Wolinsky, S. M., and Malim, M. H. (2008). APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4, e1000231.
7. Bogerd, H. P., Doehle, B. P., Wiegand, H. L., and Cullen, B. R. (2004). A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U.S.A. 101, 3770-3774.
8. Bogerd, H. P., Wiegand, H. L., Hulme, A. E., Garcia-Perez, J. L., O'Shea, K. S., Moran, J. V., and Cullen, B. R. (2006). Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 103, 8780-8785.
9. Bonvin, M., and Greeve, J. (2007). Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. J. Gen. Virol. 88, 3270-3274.
10. Bonvin, M., and Greeve, J. (2008). Hepatitis B: modern concepts in pathogenesis-APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Curr. Opin. Infect. Dis. 21, 298-303.
11. Browne, E. P., Allers, C., and Landau, N. R. (2009). Restriction of HIV-1 by APOBEC3G is cytidine deaminasedependent. Virology 387, 313-321.
12. Bulliard, Y., Turelli, P., Rohrig, U. F., Zoete, V., Mangeat, B., Michielin, O., and Trono, D. (2009). Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 83, 12611-12621.
13. Burnett, A., and Spearman, P. (2007). APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81, 5000-5013.
14. ′ on singlestranded DNA.Nat. Struct. Mol.Biol. 13, 392-399.
15. Chelico, L., Prochnow, C., Erie, D. A., Chen, X. S., and Goodman, M. F. (2010). Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285, 16195-16205.
16. Chelico, L., Sacho, E. J., Erie, D. A., and Goodman, M. F. (2008). A model for oligomeric regulation of APOBEC3G cytosine deaminasedependent restriction of HIV. J. Biol. Chem. 283, 13780-13791.
17. Chen, K. M., Harjes, E., Gross, P. J., Fahmy, A., Lu, Y., Shindo, K., Harris, R. S., and Matsuo, H. (2008). Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119.
18. Cullen,B. R. (2003). HIV-1Vif: counteracting innate antiretroviral defenses. Mol. Ther. 8, 525-527.
19. Feng, Y., and Chelico, L. (2011). Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J. Biol. Chem. 286, 11415-11426.
20. Fisher, A. G., Ensoli, B., Ivanoff, L., Chamberlain, M., Petteway, S., Ratner, L., Gallo, R. C., and WongStaal, F. (1987). The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237, 888-893.
21. Fouchier, R. A., Simon, J. H., Jaffe, A. B., and Malim, M. H. (1996). Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 70, 8263-8269.
22. Friew, Y. N., Boyko, V., Hu, W. S., and Pathak, V. K. (2009). Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 6, 56.
23. Goff, S. P. (2003). Death by deamination: a novel host restriction system for HIV-1. Cell 114, 281-283.
24. Guo, F., Cen, S., Niu, M., Saadatmand, J., and Kleiman, L. (2006). Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80, 11710-11722.
25. Guo, F., Cen, S., Niu, M., Yang, Y., Gorelick, R. J., and Kleiman, L. (2007). The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 81, 11322-11331.
26. Haché, G., Liddament, M. T., and Harris, R. S. (2005). The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280, 10920-10924.
27. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., and Malim, M. H. (2003a). DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809.
28. Harris,R. S.,Sheehy,A. M.,Craig,H. M., Malim, M. H., and Neuberger, M. S. (2003b). DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat. Immunol. 4, 641-643.
29. Holden, L. G., Prochnow, C., Chang, Y. P., Bransteitter, R., Chelico, L., Sen, U., Stevens, R. C., Goodman, M. F., and Chen, X. S. (2008). Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124.
30. Holmes, R. K., Koning, F. A., Bishop, K. N., and Malim, M. H. (2007). APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282, 2587-2595.
31. Huthoff, H., Autore, F., GalloisMontbrun, S., Fraternali, F., and Malim, M. H. (2009). RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV1. PLoS Pathog. 5, e1000330.
32. Huthoff, H., and Malim, M. H. (2007). Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 81, 3807-3815.
33. Iwatani, Y., Chan, D. S., Wang, F., Maynard, K. S., Sugiura, W., Gronenborn, A. M., Rouzina, I., Williams, M. C., Musier-Forsyth, K., and Levin, J. G. (2007). Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35, 7096-7108.
34. Iwatani, Y., Takeuchi, H., Strebel, K., and Levin, J. G. (2006). Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80, 5992-6002.
35. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., and Navaratnam, N. (2002). An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296.
36. Kaiser, S. M., and Emerman, M. (2006). Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80, 875-882.
37. KewalRamani, V. N., and Coffin, J. M. (2003). Virology. Weapons of mutational destruction. Science 301, 923-925.
38. Kitamura, S., Ode, H., and Iwatani, Y. (2011). Structural features of antiviral APOBEC3 proteins are linked to their functional activities. Front. Microbiol. 2:258.
39. Langlois, M. A., and Neuberger, M. S. (2008). Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J. Virol. 82, 4660-4664.
40. LaRue, R. S., Andresdottir, V., Blanchard,Y., Conticello, S. G., Derse, D., Emerman, M., Greene, W. C., Jonsson, S. R., Landau, N. R., Lochelt, M., Malik, H. S., Malim, M. H., Munk,C.,O'Brien,S. J.,Pathak,V. K., Strebel, K., Wain-Hobson, S., Yu, X. F.,Yuhki,N.,and Harris,R. S. (2009). Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83, 494-497.
41. Lavens, D., Peelman, F.,Van der Heyden, J., Uyttendaele, I., Catteeuw, D., Verhee, A., Van Schoubroeck, B., Kurth, J., Hallenberger, S., Clayton, R., and Tavernier,J. (2010). Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res. 38, 1902-1912.
42. Lecossier, D., Bouchonnet, F., Clavel, F., and Hance, A. J. (2003). Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112.
43. Levin, J. G., Guo, J., Rouzina, I., and Musier-Forsyth, K. (2005). Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: Critical role in reverse transcription and molecular mechanism. Prog. Nucleic Acid Res. Mol. Biol. 80, 217-286.
44. Li, X. Y., Guo, F., Zhang, L., Kleiman, L., and Cen, S. (2007). APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282, 32065-32074.
45. Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J., and Yu, X. F. (2007). Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238-7248.
46. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103.
47. Mangeat, B., Turelli, P., Liao, S., and Trono, D. (2004). A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279, 14481-14483.
48. Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C., Nymark-McMahon, H., and Landau, N. R. (2003). Speciesspecific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31.
49. Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403.
50. Mbisa, J. L., Barr, R., Thomas, J. A., Vandegraaff, N., Dorweiler, I. J., Svarovskaia, E. S., Brown, W. L., Mansky, L. M., Gorelick, R. J., Harris, R. S., Engelman, A., and Pathak, V. K. (2007). Human immunodeficiency virus type 1 cDNAs producedin the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81, 7099-7110.
51. McDougall, W. M., Okany, C., and Smith, H. C. (2011). Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes. J. Biol. Chem. 286, 30655-30661.
52. Miyagi, E., Brown, C. R., Opi, S., Khan, M., Goila-Gaur, R., Kao, S., Walker, R. C. Jr., Hirsch, V., and Strebel, K. (2010). Stably expressed APOBEC3F has negligible antiviral activity. J. Virol. 84, 11067-11075.
53. Miyagi, E., Schwartzkopff, F., Plishka, R., Buckler-White, A., Clouse, K. A., and Strebel, K. (2008). APOBEC3Gindependent reduction in virion infectivity during long-term HIV1 replication in terminally differentiated macrophages. Virology 379, 266-274.
54. Muckenfuss, H., Hamdorf, M., Held, U., Perkovic, M., Lower, J., Cichutek, K., Flory, E., Schumann, G. G., and Munk, C. (2006). APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281, 22161-22172.
55. Narvaiza, I., Linfesty, D. C., Greener, B. N., Hakata, Y., Pintel, D. J., Logue, E., Landau, N. R., and Weitzman, M. D. (2009). Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog. 5, e1000439.
56. Navaratnam, N., Bhattacharya, S., Fujino, T., Patel, D., Jarmuz, A. L., and Scott, J. (1995). Evolutionary origins of apoB mRNA editing: catalysisbyacytidinedeaminasethat has acquired a novel RNA-binding motif at its active site. Cell 81, 187-195.
57. Navarro, F., Bollman, B., Chen, H., König, R., Yu, Q., Chiles, K., and Landau, N. R. (2005). Complementary function of the two catalytic domains of APOBEC3G. Virology 333, 374-386.
58. Nguyen, D. H., Gummuluru, S., and Hu, J. (2007). Deaminationindependent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J. Virol. 81, 4465-4472.
59. Okeoma, C. M., Lovsin, N., Peterlin, B. M., and Ross, S. R. (2007). APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445, 927-930.
60. Pace, C., Keller, J., Nolan, D., James, I., Gaudieri, S., Moore, C., and Mallal, S. (2006). Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80, 9259-9269.
61. Russell, R. A., Smith, J., Barr, R., Bhattacharyya, D., and Pathak, V. K. (2009). Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83, 1992-2003.
62. Salter, J. D., Krucinska, J., Raina, J., Smith, H. C., and Wedekind, J. E. (2009). A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer selfassociation that has implications for anti-HIV function. Biochemistry 48, 10685-10687.
63. Schrofelbauer,B.,Chen,D.,and Landau, N. R. (2004). A single amino acid of APOBEC3G controls its speciesspecific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U.S.A. 101, 3927-3932.
64. Shandilya, S. M., Nalam, M. N., Nalivaika, E. A., Gross, P. J., Valesano, J. C., Shindo, K., Li, M., Munson, M., Royer, W. E., Harjes, E., Kono, T., Matsuo, H., Harris, R. S., Somasundaran, M., and Schiffer, C. A. (2010). Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18, 28-38.
65. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650.
66. Sheehy,A. M.,Gaddis,N. C.,and Malim, M. H. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407.
67. Shlyakhtenko, L. S., Lushnikov, A. Y., Li, M., Lackey, L., Harris, R. S., and Lyubchenko, Y. L. (2011). Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem. 286, 3387-3395.
68. Shubsda, M. F., Paoletti, A. C., Hudson, B. S., and Borer, P. N. (2002). Affinities of packaging domain loops in HIV-1 RNA for the nucleocapsid protein. Biochemistry 41, 5276-5282.
69. Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D. D., and Bieniasz, P. D. (2005). Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1, e6.
70. Sova, P., and Volsky, D. J. (1993). Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vifnegative human immunodeficiency virus type 1. J. Virol. 67, 6322-6326.
71. Stenglein, M. D., and Harris, R. S. (2006).APOBEC3B andAPOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281, 16837-16841.
72. Stopak, K., de Noronha, C., Yonemoto, W., and Greene, W. C. (2003). HIV1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591-601.
73. Strebel, K., Daugherty, D., Clouse, K., Cohen, D., Folks, T., and Martin, M. A. (1987). The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328, 728-730.
74. Suspène, R., Sommer, P., Henry, M., Ferris, S., Guétard, D., Pochet, S., Chester, A., Navaratnam, N., Wain Hobson, S., and Vartanian, J. P. (2004). APOBEC3G is a singlestranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32, 2421-2429.
75. Svarovskaia, E. S., Xu, H., Mbisa, J. L., Barr, R., Gorelick, R. J., Ono, A., Freed, E. O., Hu, W. -S., and Pathak, V. K. (2004). Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279, 35822-35828.
76. Takeda, E., Tsuji-Kawahara, S., Sakamoto, M., Langlois, M. A., Neuberger, M. S., Rada, C., and Miyazawa, M. (2008). Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J. Virol. 82, 10998-11008.
77. Turelli, P., Mangeat, B., Jost, S., Vianin, S., and Trono, D. (2004). Inhibition of hepatitis B virus replication by APOBEC3G. Science 303, 1829.
78. von Schwedler, U., Song, J., Aiken, C., and Trono, D. (1993). vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67, 4945-4955.
79. Wang, X., Ao, Z., Chen, L., Kobinger, G., Peng, J., and Yao, X. (2012). The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J. Virol. 86, 3777-3786.
80. Wedekind, J. E., Dance, G. S., Sowden, M. P., and Smith, H. C. (2003). Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19, 207-216.
81. Wedekind, J. E., Gillilan, R., Janda, A., Krucinska, J., Salter, J. D., Bennett, R. P., Raina, J., and Smith, H. C. (2006). Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem. 281, 38122-38126.
82. Wissing, S., Montano, M., Garcia-Perez, J. L., Moran, J. V., and Greene, W. C. (2011). Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J. Biol. Chem. 286, 36427-36437.
83. Xu, H., Svarovskaia, E. S., Barr, R., Zhang, Y., Khan, M. A., Strebel, K., and Pathak, V. K. (2004). A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U.S.A. 101, 5652-5657.
84. Yang, B., Chen, K., Zhang, C., Huang, S., and Zhang, H. (2007). Virionassociated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282, 11667-11675.
85. Yu, Q., König, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J. M., and Landau, N. R. (2004). Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442.
86. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X. F. (2003). Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060.
87. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98.
88. Zhang, L., Saadatmand, J., Li, X., Guo, F., Niu, M., Jiang, J., Kleiman, L., and Cen, S. (2008). Function analysis of sequences in human APOBEC3G involved in Vifmediated degradation. Virology 370, 113-121